A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2025

Conditions

Soft Tissue SarcomaMalignant Peripheral Nerve Sheath Tumor (MPNST)LeiomyosarcomaEndometrial Stromal Sarcoma

Interventions

DRUG

Selinexor

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER

NCT04811196 - A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | Biotech Hunter | Biotech Hunter